Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31226670 | 0.83 | ROCK1 (0.35) | ROCK1SCN10ACA2 | |
| SCHEMBL19879650 | 0.82 | HCAR2 (0.34) | HCAR2ATMCYP2A6 | |
| SCHEMBL3466815 | 0.81 | KDM4E (0.39) | ROCK1HCAR2CA2CYP2A6 | |
| SCHEMBL2400728 | 0.81 | KDM4E (0.39) | ROCK1HCAR2CA2CYP2A6 | |
| SCHEMBL19055366 | 0.81 | HCAR2 (0.33) | HCAR2CA2ATMCYP2A6 | |
| SCHEMBL28835042 | 0.79 | TACR1 (0.37) | ROCK1SCN10ACA2 | |
| SCHEMBL2559767 | 0.78 | AKT1 (0.32) | ROCK1CA2 | |
| SCHEMBL2398918 | 0.76 | CCR1 (0.43) | ROCK1CA2 | |
| SCHEMBL3466773 | 0.76 | CCR1 (0.43) | ROCK1CA2 | |
| SCHEMBL3465680 | 0.76 | APLNR (0.45) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2277865-B1 | Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2014-11-12 | — | — | EP | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| EP-1689715-B1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2011-02-09 | — | — | EP | disclosed |
| EP-2277865-A1 | Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors | YM BioSciences Australia Pty Ltd (AU) | 2011-01-26 | — | — | EP | disclosed |
| EP-2277865-A1 | Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors | YM BioSciences Australia Pty Ltd (AU) | 2011-01-26 | — | — | EP | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| EP-1689715-A4 | TUBULIN INHIBITORS | CYTOPIA RES PTY LTD (AU) | 2008-01-23 | — | — | EP | disclosed |
| EP-1689715-A1 | TUBULIN INHIBITORS | Cytopia Research Pty Ltd (AU) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054199-A1 | TUBULIN INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031835-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | ROCK1 404/4885HCAR2 4465/4885SCN10A 1599/4885 |
| US-20080194583-A1 | Tubulin Inhibitors | TUBB1, TUBB3, TUBA1C | ROCK1 456/4885HCAR2 4522/4885SCN10A 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.